KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Gsk's Net Cash Flow rose 2385.51% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year decrease of 1308.17%. This contributed to the annual value of $1.4 billion for FY2025, which is 4452.04% down from last year.
  • Per Gsk's latest filing, its Net Cash Flow stood at $1.2 billion for Q4 2025, which was up 2385.51% from -$439.8 million recorded in Q3 2025.
  • In the past 5 years, Gsk's Net Cash Flow ranged from a high of $11.0 billion in Q3 2021 and a low of -$9.5 billion during Q3 2022
  • Moreover, its 5-year median value for Net Cash Flow was $342.6 million (2023), whereas its average is $1.0 billion.
  • In the last 5 years, Gsk's Net Cash Flow crashed by 96984.5% in 2021 and then soared by 131419.83% in 2025.
  • Gsk's Net Cash Flow (Quarter) stood at $6.2 billion in 2021, then tumbled by 65.94% to $2.1 billion in 2022, then plummeted by 85.38% to $307.8 million in 2023, then soared by 213.99% to $966.5 million in 2024, then grew by 23.86% to $1.2 billion in 2025.
  • Its Net Cash Flow stands at $1.2 billion for Q4 2025, versus -$439.8 million for Q3 2025 and -$752.4 million for Q2 2025.